Based on the above contradictory results, pharmacological companies are currently developing both agonistic and antagonistic anti-TNFR2 antibodies simultaneously (38), in chance one of them may eventually be proved useful in the clinic as a cancer immunotherapeutic agent. Here, TNFRSF1B is linked to cancer.